Table 1 Characteristics of cases by study

From: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

 

SEARCH

NBCS

UBCBCS

MCCS

BCCA

Total

No. of patients

3420

1926

976

850

4040

11 212

Mean age (years, range)

52 (23–69)

54 (18–70)

48 (22–90)

60 (41–79)

59 (23–95)

55 (18–95)

Mean follow-up (years, range)

7.3 (0.5–15.9)

5.2 (0–12.6)

9.7 (0–39.4)

7.2 (0–16.2)

10.9 (0–18.5)

8.4 (0–39.4)

Number of deaths (%)

469 (14)

416 (22)

492 (50)

133 (16)

1136 (28)

2646 (24)

Annual mortality (%)

2.3

4.2

5.8

1.7

2.7

3.0

Tumour size (n (%))

 <2 cm

1272 (57)

1023 (53)

114 (12)

543 (66)

1594 (40)

5133 (52)

 2–4.9 cm

872 (39)

853 (44)

569 (62)

262 (32)

2108 (53)

4092 (42)

5 cm

93 (4)

42 (2)

238 (26)

23 (3)

301 (8)

568 (6)

Grade (n (%))

 1

624 (22)

363 (19)

68 (9)

171 (22)

211 (5)

1436 (14)

 2

1350 (47)

645 (34)

234 (32)

348 (44)

1578 (41)

4108 (41)

 3

884 (31)

907 (47)

425 (59)

265 (34)

2067 (54)

4522 (45)

Nodal status (n (%))

 Negative

1346 (62)

1218 (64)

238 (30)

521 (66)

2156 (55)

5397 (57)

 Positive

834 (38)

695 (36)

562 (70)

228 (30)

1741 (45)

4031 (43)

ER status (n (%))

 Negative

657 (20)

536 (30)

491 (55)

129 (28)

1224 (31)

3050 (29)

 Positive

2681 (80)

1253 (70)

409 (45)

333 (72)

2785 (69)

7542 (71)

PR status (n (%))

 Negative

708 (30)

772 (44)

503 (60)

222 (48)

1758 (49)

3692 (44)

 Positive

1621 (70)

993 (56)

338 (40)

237 (51)

1843 (51)

5110 (56)

HER2 status (n (%))

 Negative

1329 (89)

1341 (92)

637 (71)

407 (88)

3355 (87)

7006 (86)

 Positive

172 (11)

116 (8)

256 (29)

54 (12)

506 (13)

1094 (14)

BCL2 status (n (%))

 Negative

488 (24)

270 (27)

258 (35)

198 (43)

971 (26)

2132 (27)

 Positive

1509 (76)

714 (73)

471 (65)

265 (57)

2743 (74)

5671 (73)

  1. Abbreviations: BCCA=British Columbia Cancer Agency Case Series; BCL2=B-cell lymphoma 2; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; MCCS=Melbourne Collaborative Cohort Study; NBCS=Nottingham Breast Cancer Series; PR=progesterone receptor; SEARCH=Study of Epidemiology and Risk Factors in Cancer Heredity; UBCBCS=University of British Columbia Breast Cancer Series.